pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,307 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1008Endpoints766BioPharma Dive293BioSpace205Fierce Biotech196onclive165globenewswire health73raps
therapy area
allOncology5881Rare Disease1345Cardiology1077Hematology987Immunology984Pulmonology887Vaccines
  • EGFR-Targeted Therapy Sequencing After Resistance in NSCLC
    Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.
    onclive · 3mo ago↗ source
  • HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations
    Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.
    onclive · 3mo ago↗ source
  • Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)
    Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.
    onclive · 3mo ago↗ source
← prev
page 46 of 53
next →
73
fda recalls44
fda medwatch35
fda press26
866
Psychiatry & CNS706
Ophthalmology416
Endocrinology & Metabolism367
Pain361
Infectious Disease344
  • Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA
    Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.
    onclive · 3mo ago↗ source
  • Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response
    Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.
    onclive · 3mo ago↗ source
  • Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)
    Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.
    onclive · 3mo ago↗ source
  • Reigniting Your Curiosity During Fellowship
    Megan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.
    onclive · 3mo ago↗ source
  • STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
    The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
    STAT · 3mo ago↗ source
  • Hospital shootings steadily increased since 2000
    What the FDA has lost, why hantavirus isn't the next pandemic, and more health news from Morning Rounds
    STAT · 3mo ago↗ source
  • STAT+: Next-gen Duchenne drug from Entrada disappoints
    A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
    STAT · 3mo ago↗ source
  • STAT+: Color me skeptical: Drinking gold is not an ALS cure
    In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
    STAT · 3mo ago↗ source
  • STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
    The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
    STAT · 3mo ago↗ source
  • STAT+: What was lost at the FDA
    What was lost at the FDA: A year after DOGE’s cuts, six agency staffers describe the work they never thought they’d leave.
    STAT · 3mo ago↗ source
  • Opinion: Eugene Braunwald, ‘father of modern cardiology,’ told me he had two dreams. One came true
    Legendary cardiologist Eugene Braunwald had two visions for his career. One of them came true.
    STAT · 3mo ago↗ source
  • Cruise ship hantavirus outbreak worries experts, though they discount pandemic fears
    Scientists are worried that hantaviruses haven’t been as well studied as they ought to be, but not that the MV Hondius cruise ship is ground zero for the next pandemic.
    STAT · 3mo ago↗ source
  • MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT
    R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.
    onclive · 3mo ago↗ source
  • STAT+: Oregon hospitals won’t outsource to national physician chain after all
    Faced with stiff local opposition and a possible loss in court, PeaceHealth drops plan to replace Eugene Emergency Physicians with staffing chain ApolloMD.
    STAT · 3mo ago↗ source
  • Trump administration’s drug strategy is at odds with recent actions on funding, policy
    The White House nods to medication-assisted treatment and fentanyl test strips, despite recently placing new limits.
    STAT · 3mo ago↗ source
  • Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
    Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
    onclive · 3mo ago↗ source
  • Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
    Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.
    onclive · 3mo ago↗ source
  • Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
    Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.
    onclive · 3mo ago↗ source
  • Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
    Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.
    onclive · 3mo ago↗ source
  • FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC
    An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC
    onclive · 3mo ago↗ source
  • STAT+: Administration report on most favored nation drug pricing raises new details — and questions
    Administration report on most-favored nation drug pricing raises new details — and questions.
    STAT · 3mo ago↗ source
  • Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
    onclive · 3mo ago↗ source